Genflow Biosciences PLC Announces Company Update
Successful first regulatory interaction with the Federal Agency for Medicines and Health Products (FAHMP) And Internal Debt Restructuring First regulatory agency interaction results in recommendati...
Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. Genflow Biosciences plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
| 2.2 | |
| 2.01 | |
| - | |
| 2.2 | |
| 2 | |
| 1.323-3.406 | |
| 7 169 K | |
| 350 M | |
| 194 K | |
| 0 | |
| 2.458 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: